Janssen Of Japan To Develop ER Painkiller Patch Solely For Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Janssen Pharmaceutical, a subsidiary of U.S.-based Johnson & Johnson, has applied to develop an extended-release painkiller developed for the Japanese market. Janssen's Durotep (fentanyl) is a one-day analgesic patch, which the firm hopes to be able to begin marketing next year. The patch is available as a three-day treatment, but patients complained they needed to change the patch so they could bathe daily. Janssen used the technology of a J&J joint venture with biotech Alza to develop an extended-release version. (Click here for more - a subscription may be required